BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The grants, approved by the compensation committee, cover a total of 65,500 shares of BioCryst common stock and were issued on April 1, 2025.
The RSUs are structured to vest in four equal annual installments, with the first vesting occurring on the one-year anniversary of the grant date. Vesting is contingent upon continued employment with BioCryst. These equity awards were granted under BioCryst's Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) ha concesso unità di azioni vincolate (RSU) a 10 nuovi dipendenti come incentivo all'assunzione. Le concessioni, approvate dal comitato per la retribuzione, coprono un totale di 65.500 azioni di azioni ordinarie di BioCryst e sono state emesse il 1 aprile 2025.
Le RSU sono strutturate per maturare in quattro rate annuali uguali, con la prima maturazione che avverrà nel primo anniversario della data di concessione. La maturazione è subordinata al mantenimento dell'impiego presso BioCryst. Questi premi azionari sono stati concessi nell'ambito del Piano di Incentivazione Azionaria di BioCryst e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) ha otorgado unidades de acciones restringidas (RSU) a 10 empleados recién contratados como incentivos para la contratación. Las concesiones, aprobadas por el comité de compensación, cubren un total de 65,500 acciones de acciones ordinarias de BioCryst y fueron emitidas el 1 de abril de 2025.
Las RSU están estructuradas para adquirirse en cuatro cuotas anuales iguales, con la primera adquisición ocurriendo en el primer aniversario de la fecha de concesión. La adquisición está condicionada a la continuidad del empleo en BioCryst. Estos premios de capital se otorgaron bajo el Plan de Incentivo de Capital de Inducción de BioCryst y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX)는 10명의 신규 채용 직원에게 고용 유인으로 제한 주식 단위(RSU)를 부여했습니다. 보상 위원회에서 승인된 이 부여는 총 65,500주의 BioCryst 보통주를 포함하며, 2025년 4월 1일에 발행되었습니다.
RSU는 4회의 동등한 연간 할부로 분할 지급되도록 구조화되어 있으며, 첫 번째 지급은 부여일의 1주년 기념일에 발생합니다. 지급은 BioCryst에서의 계속적인 고용에 따라 달라집니다. 이 자본 보상은 BioCryst의 유인 자본 인센티브 계획에 따라 부여되었으며, Nasdaq 상장 규정 5635(c)(4)를 준수합니다.
BioCryst Pharmaceuticals (BCRX) a accordé des unités d'actions restreintes (RSU) à 10 nouveaux employés en tant qu'incitatifs à l'embauche. Les attributions, approuvées par le comité de rémunération, couvrent un total de 65 500 actions ordinaires de BioCryst et ont été émises le 1er avril 2025.
Les RSU sont structurées pour se libérer en quatre versements annuels égaux, le premier versement ayant lieu à la première date anniversaire de la date d'attribution. La libération est conditionnée à la poursuite de l'emploi chez BioCryst. Ces récompenses en actions ont été accordées dans le cadre du Plan d'Incitation au Capital de BioCryst et sont conformes à la règle de cotation Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) hat 10 neu eingestellten Mitarbeitern als Anreiz zur Beschäftigung beschränkte Aktieneinheiten (RSUs) gewährt. Die Vergaben, die vom Vergütungsausschuss genehmigt wurden, umfassen insgesamt 65.500 Aktien der Stammaktien von BioCryst und wurden am 1. April 2025 ausgegeben.
Die RSUs sind so strukturiert, dass sie in vier gleichen jährlichen Raten fällig werden, wobei die erste Fälligkeit am ersten Jahrestag des Vergabedatums erfolgt. Die Fälligkeit ist an die Fortsetzung der Beschäftigung bei BioCryst gebunden. Diese Eigenkapitalvergaben wurden im Rahmen des Anreiz-Eigenkapital-Incentive-Plans von BioCryst gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- New employee hiring indicates company growth and expansion
- Potential dilution of existing shareholders through 65,500 new shares
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
How many shares of RSUs did BioCryst (BCRX) grant to new employees in April 2025?
What is the vesting schedule for BioCryst's (BCRX) April 2025 RSU grants?
Under which regulatory framework were BioCryst's (BCRX) April 2025 RSUs granted?
How many new employees received RSU grants from BioCryst (BCRX) in April 2025?
